ArticleAnnals of the American Thoracic Society2022
Claims-based Prevalence of Disease Progression among Patients with Fibrosing Interstitial Lung Disease Other than Idiopathic Pulmonary Fibrosis in the United States.
Article in Annals of the American Thoracic Society, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
12 citing papers in PubMed, 19 citations in OpenAlex.
- Real-World Economic Burden Associated with Progressive Pulmonary Fibrosis in the US: An Administrative Claims Database Analysis.PharmacoEconomics · 2026Article
- Interstitial lung disease in metastatic breast cancer: a landscape review using SEER-Medicare.Breast cancer research and treatment · 2026Article
- Factors associated with delayed diagnosis of fibrotic interstitial lung disease: a retrospective cohort study.BMC pulmonary medicine · 2026Article
- Prevalence and Prognostic Impact of Progressive Pulmonary Fibrosis.Tuberculosis and respiratory diseases · 2026Review
- Observational
- Development and validation of a generalisable machine learning algorithm for identifying interstitial lung disease cohorts: a retrospective cohort study.EClinicalMedicine · 2026Article
- Electronic health record evidence suggests undercoding, underrecognition, and low antifibrotic use in progressive pulmonary fibrosis.PloS one · 2026Article
- Health care costs and utilization of progressive fibrosing lung disease by underlying interstitial lung disease type.Journal of managed care & specialty pharmacy · 2024Article
- Epidemiology and comorbidities in idiopathic pulmonary fibrosis: a nationwide cohort study.BMC pulmonary medicine · 2023Article
- Burden of illness in progressive fibrosing interstitial lung disease.Journal of managed care & specialty pharmacy · 2022Article
- Works in Progress: Using Administrative Data to Estimate the Prevalence of Progressive Fibrosing Interstitial Lung Disease.Annals of the American Thoracic Society · 2022Article
- Care patterns of patients with chronic fibrosing interstitial lung disease (ILD) with a progressive phenotype.BMC pulmonary medicine · 2022Article
Corrections and comments
- Commented on by
Authors and funding
7 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
PubMed holds no abstract for this paper.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.